Wuhan Rs Pharmaceuticals
China Updated 9 July 2026
Wuhan Rs Pharmaceuticals is an API manufacturer based in China. It holds 3 active US drug master files across a filed portfolio of 2 molecules.
1
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Sources: FDA Establishment Registration, read 4 May 2026.
Registered plants
| Site | FDA FEI |
| China, China | 3011487244 |
What they file, and where
| Molecule | Regulators | Docs |
| Azilsartan Medoxomil | US FDA | 2 |
| Nicotine | US FDA | 1 |
Also appears on these molecule pages
Comparing suppliers?
Choose your molecules and target markets. Wuhan Rs Pharmaceuticals comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability